Journal of Clinical Virology
Volume 47, Issue 1 , Pages 79-81 , January 2010

Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure

  • Sophie Stegmann

      Affiliations

    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
    • Université Paris Descartes, Paris, France
    • ,
  • Maria Elena Manea

      Affiliations

    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
    • ,
  • Charlotte Charpentier

      Affiliations

    • Université Paris Descartes, Paris, France
    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Paris, France
    • ,
  • Florence Damond

      Affiliations

    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat, Laboratoire de Virologie, Paris, France
    • ,
  • Marina Karmochkine

      Affiliations

    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
    • ,
  • Didier Laureillard

      Affiliations

    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
    • ,
  • Ali Si-Mohamed

      Affiliations

    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Paris, France
    • ,
  • Laurence Weiss

      Affiliations

    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
    • Université Paris Descartes, Paris, France
    • ,
  • Christophe Piketty

      Affiliations

    • Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
    • Corresponding Author InformationCorresponding author at: Service d’Immunologie Clinique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France. Tel.: +33 1 56 09 27 01; fax: +33 1 56 09 28 59.

Received 28 September 2009 ,Revised 5 November 2009 ,Accepted 6 November 2009.

References 

  1. Hizi A, Tal R, Hughes SH. Mutational analysis of the DNA polymerase and ribonuclease H activities of human immunodeficiency virus type 2 reverse transcriptase expressed in Escherichia coli. Virology. 1991;180:339–346
  2. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Aids. 1999;13:1477–1483
  3. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9:57–65
  4. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother. 2008;52:1545–1548
  5. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62:914–920
  6. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680-6
  7. Meyer PR, Matsuura SE, Zonarich D, Chopra RR, Pendarvis E, Bazmi HZ, et al. Relationship between 3′-azido-3′-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 2003;77:6127–6137
  8. Vrang L, Oberg B, Lower J, Kurth R. Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscarnet and 3′-azido-3′-deoxythymidine triphosphate. Antimicrob Agents Chemother. 1988;32:1733–1734
  9. Mathiesen S, Roge BT, Weis N, Lundgren JD, Obel N, Gerstoft J. Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. Aids. 2004;18:1076–1078
  10. Canestri A, Ghosn J, Wirden M, Marguet F, Ktorza N, Boubezari I, et al. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. Antivir Ther. 2006;11:561–566
  11. Charpentier C, Laureillard D, Sodqi M, Si-Mohamed A, Karmochkine M, Belec L, et al. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients. J Clin Virol. 2008;43:212–215
  12. Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol. 2005;43:4234–4236
  13. Schim van der Loeff MF, Aaby P. Towards a better understanding of the epidemiology of HIV-2. Aids. 1999;13(Suppl A):S69–84
  14. Markovitz DM. Infection with the human immunodeficiency virus type 2. Ann Intern Med. 1993;118:211–218
  15. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995;333:1662–1669
  16. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, et al. Safety and efficacy of lamivudine–zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996;276:118–125
  17. Gray G, Violari A, McIntyre J, Jivkov B, Schnittman S, Reynolds L, et al. Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants. J Acquir Immune Defic Syndr. 2006;42:169–176

PII: S1386-6532(09)00549-6

doi: 10.1016/j.jcv.2009.11.008

Journal of Clinical Virology
Volume 47, Issue 1 , Pages 79-81 , January 2010

Article Tools

* Image Usage & Resolution